340B Orphan Drug Solutions is a specialised healthcare consulting firm built exclusively around orphan drug management for expansion entity hospitals.

Founded by Dr. Lisa Nezneski, PharmD, BCPS, the firm helps Critical Access Hospitals, Rural Referral Centers, Sole Community Hospitals, and Free-Standing Cancer Hospitals navigate the 340B orphan drug exclusion and capture all available savings within and alongside the program.

Services include:
Customised orphan drug portfolio development
Split-billing software integration
Quarterly orphan drug designation updates
Manufacturer discretionary pricing monitoring, a facility-specific savings estimator, and direct specialist access.

The 340B Orphan Drug Solutions service model is built for the operational reality of expansion entity pharmacy teams, integrating seamlessly into existing workflows without requiring large internal resources. Results are measurable and consistent. Most clients see a meaningful improvement in capture rates within the first engagement quarter.

The firm backs its performance with a satisfaction commitment: facilities that do not achieve a fully streamlined program in quarter one receive an additional full quarter of support at no additional cost.